Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta(Tohoku University), Christopher J. Kemp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Molecular Cancer Therapeutics
January 28, 2021
Cited by 30


Related Papers